The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Chronic GVHD: Belumosudil and Ibrutinib for Steroid-Refractory Disease

Novel targeted therapies for chronic graft-versus-host disease management

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Hematoloji department. Book Appointment →

What is Chronic GVHD: Belumosudil and Ibrutinib for Steroid-Refractory Disease?

Chronic GVHD develops after acute GVHD or de novo with multi-organ involvement resembling autoimmune diseases.

Common organ involvement includes skin (sclerotic and lichen planus-like), oral mucosa, eyes, lungs (bronchiolitis obliterans), liver and gastrointestinal tract.

First-line corticosteroid therapy with prednisone 1 mg/kg/day with or without calcineurin inhibitor.

Ibrutinib first FDA-approved targeted therapy for steroid-refractory cGVHD inhibiting BTK in B and T cells.

Belumosudil novel ROCK2 inhibitor approved 2021 with mechanism affecting Th17 differentiation and Treg expansion.

Symptoms

Skin manifestations include sclerotic features, lichen planus-like rash, hyperpigmentation, alopecia.
Ocular involvement with dry eye syndrome and keratoconjunctivitis sicca affecting quality of life.
Oral involvement including lichenoid changes, hyposalivation and difficulty eating.
Pulmonary involvement with bronchiolitis obliterans and progressive obstructive pulmonary disease.
Hepatic involvement with cholestatic pattern and elevated bilirubin and alkaline phosphatase.

Risk Factors

Prior acute GVHD significantly increases chronic GVHD risk through ongoing alloimmune response.
HLA-mismatched donor including unrelated and haploidentical sources increase cGVHD risk.
Older recipient and donor age, female donor to male recipient increase risk.
Conditioning regimen intensity and graft characteristics including peripheral blood vs marrow source affect risk.
Donor lymphocyte infusion for relapse prevention or treatment can trigger or worsen cGVHD.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Persistent or new manifestations of cGVHD beyond day 100 post-transplant warrant comprehensive evaluation.
  • Inadequate response to first-line corticosteroid therapy after several months warrants targeted therapy consideration.
  • Pulmonary symptoms including new dyspnea or cough warrant urgent assessment for bronchiolitis obliterans.
  • Severe organ-specific manifestations may require specialized treatment including immunosuppression intensification.
  • Long-term complications including secondary malignancies, infections and metabolic effects require ongoing surveillance.

Treatment Methods

01
First-line prednisone 1 mg/kg/day for severe cGVHD with calcineurin inhibitor combination.
02
Ibrutinib 420 mg daily for steroid-refractory cGVHD with documented activity across organ systems.
03
Belumosudil 200 mg daily as alternative for steroid-refractory disease with novel mechanism and tolerability profile.
04
Ruxolitinib 10 mg twice daily as additional option for steroid-refractory cGVHD with multi-organ activity.
05
Comprehensive supportive care including topical corticosteroids and tacrolimus for skin and oral involvement, lubricating eye drops and topical cyclosporine for ocular disease, pulmonary rehabilitation and bronchodilators for lung involvement, infection prevention with antibacterial, antifungal and antiviral prophylaxis, secondary malignancy surveillance, vaccination per immune reconstitution status and quality of life support optimizes outcomes in this complex multi-system disease.

Which Department to Visit?

You can visit our Hematoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Hematoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.